

Kenneth D Westover

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8930179/publications.pdf>

Version: 2024-02-01

129
papers

8,065
citations

70961

41
h-index

51492

86
g-index

142
all docs

142
docs citations

142
times ranked

11887
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer. <i>Molecular Therapy</i> , 2022, 30, 621-631.	3.7	17
2	ADAP1 promotes latent HIV-1 reactivation by selectively tuning KRAS-ERK-AP-1 T cell signaling-transcriptional axis. <i>Nature Communications</i> , 2022, 13, 1109.	5.8	2
3	Acid-Catalyzed Synthesis of Isatoic Anhydride-8-Secondary Amides Enables IASA Transformations for Medicinal Chemistry. <i>Journal of Organic Chemistry</i> , 2022, 87, 125-136.	1.7	2
4	Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114433.	2.6	3
5	Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families. <i>Journal of Molecular Biology</i> , 2022, 434, 167626.	2.0	4
6	Thermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7095.	1.8	10
7	Loss of wild type KRAS in KRAS lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors. <i>Lung Cancer</i> , 2021, 153, 73-80.	0.9	10
8	Contact Tracing in Healthcare Settings During the COVID-19 Pandemic Using Bluetooth Low Energy and Artificial Intelligence—A Viewpoint. <i>Frontiers in Artificial Intelligence</i> , 2021, 4, 666599.	2.0	5
9	The to and fro of Rho. <i>Structure</i> , 2021, 29, 507-509.	1.6	0
10	Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay. <i>STAR Protocols</i> , 2021, 2, 100587.	0.5	1
11	The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. <i>PLoS Biology</i> , 2021, 19, e3001281.	2.6	7
12	Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. <i>Cancer Research</i> , 2021, 81, 4685-4695.	0.4	6
13	Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 220.	3.5	35
14	Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status. <i>JAMA Oncology</i> , 2021, 7, 1497.	3.4	45
15	A structural model of a Ras-Raf signalosome. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 847-857.	3.6	44
16	A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. <i>Journal of Biological Chemistry</i> , 2020, 295, 1565-1574.	1.6	17
17	Exploring Targeted Degradation Strategy for Oncogenic KRASG12C. <i>Cell Chemical Biology</i> , 2020, 27, 19-31.e6.	2.5	182
18	Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. <i>Cell Chemical Biology</i> , 2020, 27, 1229-1240.e4.	2.5	19

#	ARTICLE	IF	CITATIONS
19	Structure and Characterization of a Covalent Inhibitor of Src Kinase. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 81.	1.6	17
20	Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[<i>e</i>]pyrimido[5,4- <i>b</i>][1,4]diazepin-6-one Scaffold. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7817-7826.	2.9	16
21	GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS ^{P34R} . <i>Birth Defects Research</i> , 2020, 112, 708-717.	0.8	4
22	Discovery of a selective inhibitor of doublecortin like kinase 1. <i>Nature Chemical Biology</i> , 2020, 16, 635-643.	3.9	84
23	KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 3719-3731.	0.4	30
24	Small molecule inhibition of non-canonical (TAK1-mediated) BMP signaling results in reduced chondrogenic ossification and heterotopic ossification in a rat model of blast-associated combat-related lower limb trauma. <i>Bone</i> , 2020, 139, 115517.	1.4	9
25	Dynamic surveillance of tamoxifen-resistance in ER-positive breast cancer by CAIX-targeted ultrasound imaging. <i>Cancer Medicine</i> , 2020, 9, 2414-2426.	1.3	8
26	Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1624-1641.	2.9	27
27	Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. <i>Neuro-Oncology</i> , 2020, 22, 1831-1839.	0.6	34
28	Development of a real-time indoor location system using bluetooth low energy technology and deep learning to facilitate clinical applications. <i>Medical Physics</i> , 2020, 47, 3277-3285.	1.6	4
29	Abstract IA03: KRAS Q61H preferentially signals through the MAPK pathway in non-small cell lung cancer. , 2020, , .		0
30	Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21571-e21571.	0.8	1
31	Abstract 4017: Biochemical and biophysical characterization of a covalent inhibitor of Src kinase. , 2020, , .		0
32	Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100094.	0.6	0
33	Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma. <i>EBioMedicine</i> , 2019, 46, 105-118.	2.7	30
34	Structural basis of the atypical activation mechanism of KRASV14I. <i>Journal of Biological Chemistry</i> , 2019, 294, 13964-13972.	1.6	24
35	Green Synthesis of Substituted Anilines and Quinazolines from Isatoic Anhydride-8-amide. <i>Scientific Reports</i> , 2019, 9, 14258.	1.6	5
36	Automated Text Message Reminders Improve Radiation Therapy Compliance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1045-1052.	0.4	13

#	ARTICLE	IF	CITATIONS
37	Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 165.	3.5	15
38	Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. <i>Cell Chemical Biology</i> , 2019, 26, 792-803.e10.	2.5	103
39	Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. <i>Cell Chemical Biology</i> , 2019, 26, 818-829.e9.	2.5	43
40	Tissue-Specific Oncogenic Activity of KRASA146T. <i>Cancer Discovery</i> , 2019, 9, 738-755.	7.7	127
41	Coordinating Tissue Regeneration Through Transforming Growth Factor- β 2 Activated Kinase 1 Inactivation and Reactivation. <i>Stem Cells</i> , 2019, 37, 766-778.	1.4	10
42	Abstract 3354: Patterns of care for patients with non-operable T1-4 N+ M0 non-small cell lung cancer in the US and outcomes with radiation or chemotherapy monotherapies. , 2019, , .		0
43	Abstract 3354: Patterns of care for patients with non-operable T1-4 N+ M0 non-small cell lung cancer in the US and outcomes with radiation or chemotherapy monotherapies. , 2019, , .		0
44	Shell feature: a new radiomics descriptor for predicting distant failure after radiotherapy in non-small cell lung cancer and cervix cancer. <i>Physics in Medicine and Biology</i> , 2018, 63, 095007.	1.6	42
45	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. <i>Cell</i> , 2018, 172, 857-868.e15.	13.5	220
46	Three-dimensional printer-aided casting of soft, custom silicone boluses (SCSBs) for head and neck radiation therapy. <i>Practical Radiation Oncology</i> , 2018, 8, e167-e174.	1.1	25
47	KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation. <i>Biochemistry</i> , 2018, 57, 324-333.	1.2	40
48	Consolidative Radiotherapy for Limited Metastatic Non-“Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, e173501.	3.4	755
49	Patterns of Failure after 5 Fraction Stereotactic Ablative Radiation Therapy in Early Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e696.	0.4	0
50	Accurate real time localization tracking in a clinical environment using Bluetooth Low Energy and deep learning. <i>PLoS ONE</i> , 2018, 13, e0205392.	1.1	43
51	A pilot study using kernelled support tensor machine for distant failure prediction in lung SBRT. <i>Medical Image Analysis</i> , 2018, 50, 106-116.	7.0	22
52	GADD45 β sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level. <i>Cell Death and Disease</i> , 2018, 9, 524.	2.7	26
53	Multi-objective radiomics model for predicting distant failure in lung SBRT. <i>Physics in Medicine and Biology</i> , 2017, 62, 4460-4478.	1.6	46
54	(P084) Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Tumors Greater Than 5 cm. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, E38.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Covalent Guanosine Mimetic Inhibitors of G12C KRAS. ACS Medicinal Chemistry Letters, 2017, 8, 61-66.	1.3	59
56	Structure-guided development of covalent TAK1 inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 838-846.	1.4	28
57	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 1320-1328.	1.4	17
58	Use of Hypofractionated Radiation Therapy With Concurrent Chemotherapy in Inoperable Stage II/III Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E468.	0.4	0
59	Modern Non-operative Treatment Strategies for Patients With Stage II-III Non-small Cell Lung Cancer in the United States. International Journal of Radiation Oncology Biology Physics, 2017, 99, E468-E469.	0.4	0
60	A Support Tensor Machine Based Algorithm for Distant Failure Prediction in Lung SBRT. International Journal of Radiation Oncology Biology Physics, 2017, 99, E686-E687.	0.4	0
61	3D printer-assisted Soft Silicone Compensators for Electron Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E649.	0.4	2
62	Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF- α Inhibition for Cancer and Autoimmune Disease. Cell Chemical Biology, 2017, 24, 1029-1039.e7.	2.5	104
63	Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chemical Biology, 2017, 24, 1005-1016.e3.	2.5	109
64	KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. Structure, 2017, 25, 1442-1448.e3.	1.6	27
65	Consolidative Radiotherapy for Limited Metastatic Non-small Cell Lung Cancer: A Randomized Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1314.	0.4	2
66	Rationale for <i>RAS</i> mutation-tailored therapies. Future Oncology, 2017, 13, 263-271.	1.1	16
67	Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. Journal of Biological Chemistry, 2017, 292, 112-120.	1.6	70
68	GTP-Competitive Inhibitors of RAS Family Members. , 2017, , 155-174.		1
69	P3.02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, S2261.	0.5	1
70	P3.08-004 Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC. Journal of Thoracic Oncology, 2017, 12, S2304.	0.5	0
71	Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and β -Mangostin. PLoS ONE, 2016, 11, e0155217.	1.1	14
72	Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters. Radiotherapy and Oncology, 2016, 119, 501-504.	0.3	39

#	ARTICLE	IF	CITATIONS
73	A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. <i>Nature Chemical Biology</i> , 2016, 12, 452-458.	3.9	389
74	A Phase III Randomized Study of Image Guided Conventional (60 Gy/30 fx) Versus Accelerated, Hypofractionated (60 Gy/15 fx) Radiation for Poor Performance Status Stage II and III NSCLC Patientsâ€™ An Interim Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E451.	0.4	19
75	Safety Analysis From a Prospective Registry Study of Stereotactic Body Radiation Therapy for Aggressive Management of Late-Stage Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E527.	0.4	1
76	Direct Targeting of β -Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/ β -Catenin Signaling. <i>Cell Reports</i> , 2016, 16, 28-36.	2.9	98
77	Predicting Distant Failure in Lung Stereotactic Body Radiation Therapy Using Multiobjective Radiomics Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S193-S194.	0.4	2
78	Data publication with the structural biology data grid supports live analysis. <i>Nature Communications</i> , 2016, 7, 10882.	5.8	113
79	Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching. <i>Journal of Molecular Biology</i> , 2016, 428, 4723-4735.	2.0	30
80	Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. <i>Radiation Research</i> , 2016, 185, 527-538.	0.7	11
81	Progress on Covalent Inhibition of KRASG12C. <i>Cancer Discovery</i> , 2016, 6, 233-234.	7.7	21
82	Safety and tolerability of concurrent Nab-P (Nab-P) and Carbo (Carbo) with thoracic radiotherapy (RT) followed by consolidative Nab-P and Carbo in patients with stage IIIA/B non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20046-e20046.	0.8	0
83	Structural dataset for the fast-exchanging KRAS G13D. <i>Data in Brief</i> , 2015, 5, 572-578.	0.5	5
84	Neutrophilâ€™Lymphocyte and Plateletâ€™Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Nonâ€™Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 280-285.	0.5	154
85	Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. <i>Molecular Cancer Research</i> , 2015, 13, 1325-1335.	1.5	503
86	SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 89, 87-93.	0.9	13
87	Development of small molecules targeting the pseudokinase Her3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3382-3389.	1.0	53
88	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 72-81.	0.4	62
89	Discovery of Type II Inhibitors of TGF β -Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase 2 (MAP4K2). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 183-196.	2.9	62
90	Abstract LB-031: Biochemical profiling of cancer-associated KRAS mutants: clues towards an understanding of differential clinical outcomes. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
91	Abstract 2852: Torin2 suppresses ionizing radiation induced DNA damage repair. , 2015, , .		0
92	Abstract A178: Structure guided development of irreversible inhibitors for TAK1. , 2015, , .		0
93	Radiation Therapy as a Backbone of Treatment of Locally Advanced Non-Small Cell Lung Cancer. Seminars in Oncology, 2014, 41, 57-68.	0.8	18
94	Therapeutic Targeting of Oncogenic Kâ€Ras by a Covalent Catalytic Site Inhibitor. Angewandte Chemie - International Edition, 2014, 53, 199-204.	7.2	262
95	Pharmacological targeting of the pseudokinase Her3. Nature Chemical Biology, 2014, 10, 1006-1012.	3.9	161
96	Development and Experience With an EMR-Based Radiation Oncology Toxicity Recording Instrument (ROTOX): Benchmarking and Quality Improvement. International Journal of Radiation Oncology Biology Physics, 2014, 90, S820.	0.4	0
97	Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Prognostic Factors Following Stereotactic Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S621.	0.4	3
98	In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8895-8900.	3.3	193
99	Abstract PR07: Crystal structure of K-Ras G12C bound to an active site inhibitor. , 2014, , .		0
100	Genome-wide distribution of histone H4 Lysine 16 acetylation sites and their relationship to gene expression. Genome Integrity, 2013, 4, 3.	1.0	46
101	Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR. Cancer Research, 2013, 73, 2574-2586.	0.4	170
102	Stereotactic Ablative Radiotherapy (SABR) for Nonâ€Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 845-854.	0.8	29
103	Developments in stereotactic ablative radiotherapy for the treatment of early-stage lung cancer. Lung Cancer Management, 2013, 2, 129-139.	1.5	0
104	Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. Journal of Biological Chemistry, 2012, 287, 9742-9752.	1.6	89
105	Proton SBRT for Medically Inoperable Stage I NSCLC. Journal of Thoracic Oncology, 2012, 7, 1021-1025.	0.5	61
106	Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition. Cell, 2012, 150, 987-1001.	13.5	723
107	Treatment of Non-Small Cell Lung Cancer Patients With Proton Beam-Based Stereotactic Body Radiotherapy: Dosimetric Comparison With Photon Plans Highlights Importance of Range Uncertainty. International Journal of Radiation Oncology Biology Physics, 2012, 83, 354-361.	0.4	52
108	Radical prostatectomy vs radiation therapy and androgenâ€suppression therapy in highâ€risk prostate cancer. BJU International, 2012, 110, 1116-1121.	1.3	46

#	ARTICLE	IF	CITATIONS
109	Outcomes of Proton Beam Based SBRT in Medically Inoperable Stage I NSCLC. International Journal of Radiation Oncology Biology Physics, 2011, 81, S616-S617.	0.4	0
110	Significance testing as perverse probabilistic reasoning. BMC Medicine, 2011, 9, 20.	2.3	24
111	Should a Sentinel Node Biopsy Be Performed in Patients with High-Risk Breast Cancer?. International Journal of Breast Cancer, 2011, 2011, 1-5.	0.6	0
112	SU-E-T-545: Assessing the Impact of Proton Range Uncertainties on NSCLC Lung Patients Treated with Proton Beam-Based SBRT. Medical Physics, 2011, 38, 3614-3614.	1.6	0
113	Impact of Superposition/convolution Dose Algorithm Inaccuracies in SBRT of Patients with Early Stage NSCLC: A Monte Carlo Study. International Journal of Radiation Oncology Biology Physics, 2010, 78, S792.	0.4	0
114	Should a Sentinel Node Biopsy be Performed in Patients with High Risk Breast Cancer?. International Journal of Radiation Oncology Biology Physics, 2010, 78, S256-S257.	0.4	0
115	Comprehensive and Efficient <i>HBB</i> Mutation Analysis for Detection of \hat{I}^2 -Hemoglobinopathies in a Pan-Ethnic Population. American Journal of Clinical Pathology, 2010, 133, 700-707.	0.4	28
116	Structural Basis of Transcription: Backtracked RNA Polymerase II at 3.4 Angstrom Resolution. Science, 2009, 324, 1203-1206.	6.0	225
117	SU-FF-T-650: Dosimetric Benefit of a Combination of Respiratory-Gating, Image-Guidance and Intensity Modulated Radiation Therapy for Pancreatic Cancer Treatment. Medical Physics, 2009, 36, 2674-2674.	1.6	0
118	Mycotic aneurysm of the left main coronary artery producing acute coronary occlusion and purulent pericarditis. International Journal of Cardiology, 2007, 114, E81-E82.	0.8	12
119	Structural basis of RNA polymerase II substrate specificity and catalysis. FASEB Journal, 2007, 21, A656.	0.2	0
120	Structural Basis of Transcription: Role of the Trigger Loop in Substrate Specificity and Catalysis. Cell, 2006, 127, 941-954.	13.5	421
121	Structural basis of eukaryotic gene transcription. FEBS Letters, 2005, 579, 899-903.	1.3	120
122	Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. American Journal of Veterinary Research, 2004, 65, 810-818.	0.3	75
123	Structural Basis of Transcription: Separation of RNA from DNA by RNA Polymerase II. Science, 2004, 303, 1014-1016.	6.0	231
124	Structural Basis of Transcription: An RNA Polymerase II-TFIIB Cocrystal at 4.5 Angstroms. Science, 2004, 303, 983-988.	6.0	307
125	Diffusion of nucleoside triphosphates and role of the entry site to the RNA polymerase II active center. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17361-17364.	3.3	66
126	Structural Basis of Transcription. Cell, 2004, 119, 481-489.	13.5	248

#	ARTICLE	IF	CITATIONS
127	Structural Basis of Transcription. <i>Cell</i> , 2004, 119, 1055.	13.5	2
128	Nonsteroidal Anti-Inflammatory Drugs, Acetaminophen, Cyclooxygenase 2, and Fever. <i>Clinical Infectious Diseases</i> , 2000, 31, S211-S218.	2.9	70
129	Mechanism of Rab Geranylgeranylation:Â Formation of the Catalytic Ternary Complexâ€. <i>Biochemistry</i> , 1998, 37, 12559-12568.	1.2	81